SynthesisPloS one2019
An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
Synthesis in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.In vivo (Athens, Greece)Trial
- Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal.Cancers · 2026Review
- Efficacy and safety of metronomic oral vinorelbine in elderly patients with locally advanced and metastatic non-small cell lung cancer.BMC cancer · 2026Article
- Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLC.Lung cancer management · 2025Article
- Review
- Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer.Cancer chemotherapy and pharmacology · 2022Article
- Home-deliverable antitumoral treatments in the age of COVID-19: the Portsmouth experience and a narrative review.Mediastinum (Hong Kong, China) · 2022Review
- Metronomic Chemotherapy.Cancers · 2021Review
- Metronomic chemotherapy in non-small cell lung cancer.Oncology letters · 2020Review
- Older cancer patients and COVID-19 outbreak: Practical considerations and recommendations.Cancer medicine · 2020Review
- Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.Lung cancer (Amsterdam, Netherlands) · 2020Article
- Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience.Oncology research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral non-comparative phase II studies have evaluated metronomic oral vinorelbine (MOV) in metastatic non-small cell lung cancer (NSCLC) but the small size of each study limits their conclusions. PURPOSE: To perform an individual patient-data metaanalysis of studies evaluating MOV in metastatic NSCLC in order to measure survival and safety of treatment with this regimen.
methodsStudies were selected if (1) administration of oral vinorelbine thrice a week; (2) fixed daily dose comprised between 30 and 50 mg, and; (3) being published before October 4th 2018. Database encompassed 8 variables characterizing disease and demography, 3 informing therapy, and 12 describing survival and toxicity.
resultsNine studies encompassing 418 patients fulfilled the selection criteria, 80% of them having frailty characteristics. Median overall survival (OS) was 8.7 months (95%CI: 7.6-9.5). OSrates at 6 months, one year and at two years after starting vinorelbine were 64%, 30.3% and 8.9%, respectively. In the Cox model, Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2, and anemia of any grade were significant determinants of shorter OS. Median progression-free survival(PFS) was 4.2 months (95%CI: 3.9-5). At 6 months and at one-year, PFS rates were 35% and 11.9% respectively. In the Cox model stratified for the variable "study", PS = 2and stage IV were significant determinants of shorter PFS. No toxicity was reported for 40% of patients, and 66 (15.8%) patients experienced a grade 3-4 toxicity. The most frequent toxicity was anemia of any grade (35.8%) that was higher with the 50 mg dosage.
conclusionMOV is an active and well-tolerated chemotherapy in metastatic NSCLC and is a manageable therapy in frail patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.